SCHEMBL23978280

SCHEMBL23978280

O=C(O)c1ccc(COc2ccc(Cl)cc2)c(F)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 7/20 0.66
MRGPRX4 Q96LA9 3/20 0.58
MAOB P27338 3/20 0.57
NR4A1 P22736 1/20 0.54
NR4A3 Q92570 1/20 0.54
PPARA Q07869 2/20 0.52
RXRA P19793 1/20 0.51
RXRB P28702 1/20 0.51
RXRG P48443 1/20 0.51
KDM5A P29375 1/20 0.51
KDM5B Q9UGL1 1/20 0.51
MEN1 O00255 1/20 0.50
NPC1 O15118 1/20 0.50
POLB P06746 1/20 0.50
RAB9A P51151 1/20 0.50
KMT2A Q03164 1/20 0.50
SENP8 Q96LD8 1/20 0.50
SENP7 Q9BQF6 1/20 0.50
SENP6 Q9GZR1 1/20 0.50
PARP15 Q460N3 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23978033 0.90 MRGPRX4 (0.69) NR4A2MRGPRX4MAOBNR4A1NR4A3
SCHEMBL20772861 0.83 MAOB (0.51) NR4A2MRGPRX4MAOBNR4A1NR4A3
SCHEMBL23978219 0.79 NR4A2 (0.60) NR4A2MRGPRX4MAOBNR4A1NR4A3
SCHEMBL23978010 0.79 NR4A2 (0.60) NR4A2MRGPRX4MAOBNR4A1NR4A3
SCHEMBL23978221 0.78 NR4A2 (0.59) NR4A2MRGPRX4MAOBNR4A1NR4A3
SCHEMBL20775325 0.77 MAOB (0.50) NR4A2MRGPRX4MAOBPPARARXRA
SCHEMBL20772736 0.77 MRGPRX4 (0.64) NR4A2MRGPRX4MAOBNR4A1NR4A3
SCHEMBL15936021 0.77 NR4A2 (0.54) NR4A2MRGPRX4MAOBNR4A1NR4A3
SCHEMBL1444784 0.76 MAOB (0.75) NR4A2MAOBNR4A1NR4A3NPC1
SCHEMBL3980330 0.76 NR4A2 (0.64) NR4A2MRGPRX4NR4A1NR4A3RXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210346405-A1 BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS INCORPORATED 2021-11-11 US disclosed
WO-2021222174-A1 BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS INCORPORATED (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210346405-A1 BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS BCL2, BCL2L2, BCL2L1 NR4A2 3359/4885MRGPRX4 4677/4885MAOB 2890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.